ArticlePharmacoEconomics - open2023
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.
Article in PharmacoEconomics - open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- AI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis.Digestive diseases and sciences · 2026Article
- Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.Journal of obesity & metabolic syndrome · 2026Review
- Imaging Evaluation for Steatotic Liver Disease.Korean journal of radiology · 2026Review
- Cost-Effectiveness of Blood-Based Fibrosis Screening in High-Risk Metabolic Liver Diseases With Emerging Therapies.Gastro hep advances · 2026Article
- Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Article
- Bioavailable human metabolites from TOTUM-448 (plant-based formulation) maintain liver cell functionality in a hyperlipidic context that drives MASLD onset.Scientific reports · 2025Article
- Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials.Archives of pharmacal research · 2025Review
- Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.Seminars in liver disease · 2025Review
- Totum-448 Improves MASLD and Modulates Microbiota in Hamsters: Dose-Response Study and Effects of Supplementation Cessation.Food science & nutrition · 2025Article
- Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests.Scientific reports · 2025Article
- Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment.Clinical and molecular hepatology · 2025Review
- Resmetirom-eligible population among US adults: An estimation analysis based on NHANES 2017-March 2020.Hepatology communications · 2025Article
- Value-Based Pricing of Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease.JAMA network open · 2025Article
- Article
- Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.Journal of medicinal chemistry · 2025Article
- Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).Portal hypertension & cirrhosis · 2025Article
- Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort.Hepatology forum · 2025Article
- Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful?Current vascular pharmacology · 2025Article
- The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC.Frontiers in immunology · 2025Review
- Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study.Journal of comparative effectiveness research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic steatohepatitis (NASH) is characterized by inflammation and hepatocellular damage caused by accumulation of fat in the liver. Resmetirom (MGL-3196) is an orally administered, small-molecule, liver-targeted, selective thyroid hormone receptor-β agonist. This early analysis explored the potential cost effectiveness of resmetirom for the treatment of NASH from a US commercial payer perspective.
methodsAn early economic model was developed to reflect the clinical pathways typically followed by patients with NASH and liver fibrosis. Use of resmetirom, compared with placebo, was assessed. The Markov model structure was informed by a previous modeling study and a randomized, double-blind, placebo-controlled, phase II trial of resmetirom. Costs and outcomes were assessed over a lifetime time horizon with results presented in terms of cost per quality-adjusted life-year (QALY) gained.
resultsResmetirom treatment resulted in increased costs of US$66,764 per patient, while increasing QALYs by 1.24. The incremental cost-effectiveness ratio was US$53,929 per QALY gained, indicating resmetirom treatment would potentially be cost effective at a willingness-to-pay (WTP) threshold of US$100,000. Results indicated that resmetirom would reduce the lifetime number of cases of decompensated cirrhosis (- 87), hepatocellular carcinoma (- 59), and liver transplants (- 30) per 1,000 patients compared with placebo. Resmetirom treatment remained cost effective at a US$100,000 WTP threshold up to a daily price point of US$72.00.
conclusionResmetirom is a potentially cost-effective treatment option for patients with NASH and liver fibrosis based on an analysis performed from a US commercial payer perspective. Future economic analyses of the technology should, however, focus on overcoming the limitations of existing modeling methodology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.